NAMS NewAmsterdam Pharma Company NV Forecast, Technical & Fundamental Analysis
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated... Show more
NAMS is expected to report earnings to rise 20.82% to -48 cents per share on August 12
Q2'26
Est.
$-0.48
Q1'26
Beat
by $0.09
Q4'25
Missed
by $0.23
Q3'25
Missed
by $0.21
Q2'25
Beat
by $0.34
The last earnings report on May 07 showed earnings per share of -40 cents, beating the estimate of -49 cents. With 227.19K shares outstanding, the current market capitalization sits at 3.89B.
A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with PTGX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then PTGX could also see price increases.
NAMS in +5.87% Uptrend, advancing for three consecutive days on June 24, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NAMS advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 23, 2026. You may want to consider a long position or call options on NAMS as a result. In of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on June 24, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in of 59 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for NAMS crossed bullishly above the 50-day moving average on July 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for NAMS moved out of overbought territory on July 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where NAMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
NAMS moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for NAMS moved below the 200-day moving average on June 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NAMS broke above its upper Bollinger Band on July 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NAMS entered a downward trend on June 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NAMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.848) is normal, around the industry mean (22.746). P/E Ratio (0.000) is within average values for comparable stocks, (37.261). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.488). NAMS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (175.439) is also within normal values, averaging (432.117).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
